Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RF16001
- Development stage
- Unknown
- Lead developer
- Yichang Humanwell Pharmaceutical
- Modality
- Small Molecules
- Administration
- Injection
01
Overview
RF16001 is an investigational small molecule, long-acting local anesthetic developed by Wuhan Humanwell Hi-Tech Industry. It is currently in Phase 2 clinical development for the management of postoperative pain (postoperative analgesia). As a Class 1 new chemical entity in China, RF16001 is designed to provide prolonged pain relief at the surgical site following administration via injection. Its mechanism of action involves the blockade of voltage-gated sodium channels, which inhibits the initiation and conduction of nerve impulses, thereby preventing the transmission of pain signals to the central nervous system.
- Other names
- 注射用RF16001
02
Targets
NaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on RF16001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RF16001.